Rethinking ovarian cancer: recommendations for improving outcomesSebastian Vaughan, Frances R. Balkwill, Amit M. Oza et al.|Nature reviews. Cancer|2011Cited by 1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancerDavid D.L. Bowtell, Frances R. Balkwill, Steffen Böhm et al.|Nature reviews. Cancer|2015Cited by 1.4k
Spatial and Temporal Heterogeneity in High-Grade Serous Ovarian Cancer: A Phylogenetic AnalysisRoland F. Schwarz, James D. Brenton|PLoS Medicine|2015Cited by 416
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trialAndrew R. Clamp, Jonathan A. Ledermann, Elizabeth C James et al.|The Lancet|2019Cited by 223
ICON8: A GCIG phase III randomised trial evaluating weekly dose- dense chemotherapy integration in first-line epithelial ovarian/fallopian tube/primary peritoneal carcinoma (EOC) treatment: Results of primary progression- free survival (PFS) analysisA. Clamp, Jonathan A. Ledermann, Iain A. McNeish et al.|Annals of Oncology|2017Cited by 51